Citations

Clear

16280 citation(s) found for "Yu, David".

Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Ip, James E. , Coutu, Benoit , Noseworthy, Peter A. , Parody, Maria Leonor, Rafii, Farhad, Stambler, Bruce S. , Tahirkheli, Naeem , Uribe, Juan Fernando Agudelo , Hu, Derek , Shardonofsky, Silvia, Sheikh, Mohamud, Holz, Anita, Bharucha, David B. , Camm, A. John, Noseworthy, Peter A , Sears, Samuel F , Stambler, Bruce S , Agudelo-Uribe, Juan , Ip, James E. , Sears, Samuel F. , Singh, Narendra Kumar , Sheikh, Muhammad B., Holz, Anita, Camm, Alan John

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 11, 2025 | Volume: 36 | Issue: 11 | Pages: 2990-3003

10.1111/jce.70086 | PMID 40931676 Get It

ABSTRACT Introduction Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an open‐label, single‐arm study that evaluated etripamil for multiple, at‐home PSVT episodes, without test dose before first use. Methods Patients applied an ECG monitor at symptom onset and self‐administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70‐mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment‐emergent adverse events (TEAEs) and ECG arrhythmia‐surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes. Results 1054 perceived PSVT episodes were etripamil‐treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2–25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes. Conclusions Etripamil nasal spray self‐administered in a real‐world setting was well tolerated, effective, and had a consistent safety profile as a single‐ or repeat‐dose regimen across multiple PSVT episodes. Trial Registration: ClinicalTrials.gov NCT04072835
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418

10.6004/jnccn.2025.0042 | PMID 40930144 Get It

The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
Predictive Value of Plasma Biomarkers in Tau‐ PET Transitions
Graff‐Radford, Jonathan , Syrjanen, Jeremy A. , Vemuri, Prashanthi , Lowe, Val J. , Schwarz, Christopher G. , Wiste, Heather J. , Kremers, Walter K. , Binette, Alexa Pichet , Stomrud, Erik , Petersen, Ronald C. , Algeciras-Schimnich, Alicia , Pichet Binette, Alexa , Knopman, David S. , Petersen, Ronald C , Hansson, Oskar , Schwarz, Christopher G , Vemuri, Prashanthi , Stomrud, Erik , Kremers, Walter K , Algeciras‐Schimnich, Alicia , Smith, Ruben , Mattsson, Niklas , Palmqvist, Sebastian , Knopman, David S. , Cogswell, Petrice M. , Hansson, Oskar , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | September 10, 2025 | Volume: 98 | Issue: 6 | Pages: 1249-1260

10.1002/ana.78003 | PMID 40927954 Get It

Objective The objective of this study was to determine the predictive value of amyloid‐positron emission tomography (PET) versus the plasma ratio of phosphorylated tau at threonine 217 (p‐tau217) to non‐phosphorylated tau217 (%p‐tau217) for tau‐PET transitions (T− to T+). The added value of combining plasma amyloid‐β 42 and amyloid‐β 40 (Aβ42/40) and %p‐tau217 into an amyloid probability score (APS2) was also assessed. Methods Mayo Clinic Study of Aging (MCSA) participants had plasma markers measured at via mass spectrometry (MS), an amyloid‐PET scan, and a tau‐PET (meta‐temporal region of interest [ROI]) negative scan (standardized uptake value ratio [SUVR] <1.29) at the index (baseline) date, along with one or more follow‐up tau‐PET scans. The BioFINDER‐2 cohort was used for validation. Cox proportional hazards models adjusted for age, sex, and apolipoprotein ( APOE ) ε4 were used to assess predictors, with scaling to the interquartile range (IQR) for comparability of hazard ratios (HR). Results Among 255 tau‐PET negative MCSA participants (median age: 71.9 years), 37 converted to tau‐PET positive (median follow‐up time: 3.81 years). Higher %p‐tau217 (HR: 1.52 [95% CI: 1.28–1.80]), amyloid‐PET centiloid (HR: 1.47 [95% CI: 1.20–1.79]), and APS2 (HR: 1.62 [95% CI: 1.22–2.16]) predicted tau‐PET conversion. However, Aβ42/40 (HR: 0.94 [95% CI: 0.54–1.66]) was not associated with tau‐PET conversion. In the BioFINDER‐2 cohort (605 tau‐negative, median age: 70.2), 33 converted to tau‐positive (median follow‐up time: 2 years), with higher %p‐tau217 (HR: 1.80 [95% CI: 1.50–2.17]), amyloid‐PET centiloid (HR: 2.29 [95% CI: 1.77–2.97]), and lower Aβ42/40 (HR: 2.38 [95% CI: 1.17–4.83]) predicting conversion. Interpretation In two cohorts, %p‐tau217 was associated with tau‐PET conversion, comparable to amyloid‐PET. APS2 also predicted conversion in the MCSA cohort, whereas Aβ42/40 predicted conversion in the BioFINDER‐2 cohort, which had more individuals with cognitive impairment. ANN NEUROL 2025;98:1249–1260
Race, Ethnicity, and Antiemetic Management: Reply
Milam, Adam J. , Milam, Adam J , Burton, Brittany N. , Warner, David O.

Mayo Clinic

Anesthesiology | September 9, 2025 | Volume: 143 | Issue: 4 | Pages: 1135-1136

10.1097/aln.0000000000005644 | PMID 40923838 Get It

Sulcal morphology in former American football players
Jung, Leonard , Mirmajlesi, Anya S, Stearns, J. W. , Breedlove, Katherine M. , John, Omar , Kim, Nicholas , Wickham, Alana, Protas, Hillary , Baucom, Zachary, Tuz‐Zahra, Fatima , Wiegand, Tim L. T. , Billah, Tashrif , Pasternak, Ofer, Im, Brian , Datta, Shae , Bernick, Charles , Balcer, Laura J. , Alosco, Michael L. , Lin, Alexander , Cummings, Jeffrey L., Reiman, Eric M. , Arciniega, Hector , Boker, Connie, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Pasternak, Ofer , Arcinieago, Hector, Coello, Eduardo , Coleman, Michael J. , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Marmar, Charles R. , Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard M., Johnson, Keith A. , Jung, Leonard B , Stearns, Jared , Breedlove, Katherine , Tripodis, Yorghos , Adler, C H , Alosco, Michael L , Koerte, Inga K , Arciniega, Hector , Su, Yi , Tripodis, Yorghos , Daneshvar, Daniel H. , Heller, Carina , Coleman, Michael , Adler, Charles H. , Stern, Robert A. , Shenton, Martha E. , Bouix, Sylvain , Chen, Kewei , Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Katz, Douglas I. , Mez, Jesse , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Miller, Jason Rafe , Sabbagh, Marwan Noel , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Bellgowan, Patrick S.F. , Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Kirov, Ivan I. , Lui, Yvonne W. , George, Allan, Riley, Edward P. , Cummings, Jeffrey L.

Mayo Clinic

Brain Communications | September 9, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcaf345 | PMID 41048544 Get It

Abstract Repetitive head impacts are associated with structural brain changes and an increased risk for chronic traumatic encephalopathy, a progressive neurodegenerative disease that can only be diagnosed after death. Chronic traumatic encephalopathy is defined by the abnormal accumulation of phosphorylated tau protein, particularly at the depths of the superior frontal sulci, suggesting that sulcal morphology may serve as a relevant structural biomarker. Contact sport athletes, such as former football players, are at elevated risk due to their prolonged exposure to repetitive head impacts. Cortical atrophy linked to underlying tau accumulation may result in shallower and wider sulci, potentially making sulcal morphology an imaging marker for identifying individuals at risk for this disease. This study investigated sulcal morphological differences in former football players and examined associations with age, football-related exposure, clinical diagnosis of traumatic encephalopathy syndrome, levels of certainty for chronic traumatic encephalopathy pathology, neuropsychological performance, and positron emission tomography imaging using flortaucipir. We analysed structural magnetic resonance imaging data from 169 male former football players (mean age 57.2 (8.2) years, range 45–74) and 54 age-matched, unexposed asymptomatic male controls (mean age 59.4 (8.5) years, range 45–74). Sulcal depth and width were quantified using the CalcSulc, focusing on two regions in each hemisphere commonly affected by chronic traumatic encephalopathy pathology: the superior frontal and occipitotemporal sulci. Generalized least squares models were used to assess group differences and interactions with age and football exposure variables, including age of first exposure, total years played, and cumulative head impact exposure. An analysis of covariance evaluated relationships between sulcal morphology, clinical measures, and flortaucipir uptake, adjusting for age, race, body mass index, education, imaging site, apolipoprotein E4 status, and total intracranial volume. Former football players demonstrated significantly shallower sulcal depth in the left superior frontal sulcus compared to unexposed controls. Earlier age of first exposure and longer football careers were associated with greater widening of the left occipitotemporal sulcus. Higher cumulative head impact exposure was linked to reduced sulcal depth in the left superior frontal region. However, sulcal morphology was not associated with clinical diagnosis, levels of certainty, neuropsychological test performance, or flortaucipir imaging. These findings suggest that sulcal morphology may reflect cumulative exposure to repetitive head impacts, particularly in brain regions vulnerable to chronic traumatic encephalopathy pathology. Future ante- and post-mortem validation studies are needed to determine whether sulcal morphology can serve as a reliable in vivo biomarker of risk.
Distinct clinical, laboratory, molecular, and pathologic features of systemic mastocytosis involving the gastrointestinal tract
Chiu, April , Viswanatha, David S., He, Rong , Reichard, Kaaren K. , Tefferi, Ayalew, Pardanani, Animesh , Chen, Dong , Majerus, Julie A. , Chen, Dong , Tefferi, Ayalew

Mayo Clinic

Am J Clin Pathol | September 9, 2025 | Volume: 164 | Issue: 6 | Pages: 879-889

10.1093/ajcp/aqaf112 | PMID 41293991 Get It

Abstract Objective Gastrointestinal (GI) symptoms are common in systemic mastocytosis (SM). We hereby report the clinicopathologic and molecular features of GI mastocytosis. Methods The study includes 104 patients with suspected SM. Of 258 GI biopsy ­specimens, 33 (20 patients, 19%) were mastocytosis-positive, with 19 (16 patients) initially missed. Results Tryptase (n = 29) was weakly positive/negative in two-thirds of the mastocytosis-positive GI biopsy specimens. Additional immunohistochemistry (n = 23) showed positive mast cell expression for CD30 (n = 2), CD123 (n = 7), and PD-L1 (n = 12), as well as increased PD-1–positive cells (n = 4). Sixty patients had positive bone marrow (BM) for SM (SM-BM+), including 19 with positive GI biopsy specimens (SM-GI+). Almost all (43/44) SM-BM– patients were SM-GI–. The SM-GI vs SM-BM status showed high positive predictive value (95%) and specificity (98%). Patients with SM with mastocytosis-positive vs mastocytosis-negative GI biopsy specimens had higher serum tryptase levels (P = .04). KIT D816V mutation was detected in 7 of 13 and 12 of 13 mastocytosis-positive GI biopsy specimens using allele-specific polymerase chain reaction and droplet digital polymerase chain reaction (ddPCR), respectively. Conclusions GI mastocytosis is highly predictive of SM in BM; however, most SM-BM+ patients are SM-GI–. The SM-BM– patients are very unlikely to be SM-GI+. Because GI neoplastic mast cells are often tryptase negative, diagnostic evaluation should include CD117 and CD25 immunohistochemistry, as well as KIT D816V mutation analysis by ddPCR as needed.
Neutrophil-to-Lymphocyte Ratio as a Biomarker in Clinically Stable Chronic Obstructive Pulmonary Disease: SPIROMICS Cohort
HOESTEREY, DANIEL , Markovic, Daniela , Buhr, Russell G. , Tashkin, Donald P., Barr, R. Graham, Belperio, John A. , Bowler, Russell P. , Bleecker, Eugene R., Couper, David J., Cooper, Christopher B. , Han, MeiLan K., Hansel, Nadia N. , Hastie, Annette T. , Hoffman, Eric A. , Kanner, Richard E. , O’Neal, Wanda K. , Ortega, Victor E. , Paine, Robert, Shrivastav, Abhishek K., Wells, J. Michael , Woodruff, Prescott G. , Hoesterey, Daniel T , Buhr, Russell G , Bowler, Russell P , Doerschuk, Claire M , Drummond, M Bradley , Hastie, Annette T , Hoffman, Eric A , Huang, Yvonne J , Krishnan, Jerry A , Wells, J Michael , Curtis, Jeffrey L , O'Neal, Wanda K , Dang, Hong , Barr, R. Graham, Couper, David J., Criner, Gerard J. , Doerschuk, Claire M. , Dransfield, Mark T. , Drummond, Michael , Fawzy, Ashraf , Freeman, Christine M. , Han, MeiLan King , Kaner, Robert J. , Kim, Victor, Martínez, Fernando J. , Shrivastav, Abhishek K., Curtis, Jeffrey L. , Barjaktarević, Igor

Mayo Clinic

Annals of the American Thoracic Society | September 8, 2025 | Volume: 22 | Issue: 12 | Pages: 1881-1890

10.1513/annalsats.202412-1265oc | PMID 40920896 Get It

Abstract Rationale Inflammation is central to chronic obstructive pulmonary disease (COPD) pathogenesis but incompletely represented in COPD prognostic models. The neutrophil-to-lymphocyte ratio (NLR) is a readily available inflammatory biomarker. Objectives To explore the associations of NLR with smoking status, clinical features of COPD, and future adverse outcomes. Methods We analyzed NLR calculated from the complete blood count of participants who currently or formerly smoked (n = 2,624) and tobacco-naive control subjects (n = 187) in the SPIROMICS multicenter observational cohort study. We assessed the stability of NLR at 6 weeks and 1 year, the association with select blood biomarkers, and the impact of smoking on NLR and cell counts. We stratified participants by NLR quartiles to compare cross-sectional clinical features at enrollment, prospectively observed exacerbations at 1 year, and mortality during longitudinal follow up. Results Higher NLR quartiles were broadly associated with more severe clinical features of COPD. NLR values were repeatable at 6 weeks (intraclass correlation coefficient, 0.74) and 1 year (intraclass correlation coefficient, 0.62). The impact of smoking on NLR varied with the severity of airflow limitation, mediated by an interaction between smoking, forced expiratory volume in 1 second percent predicted, and neutrophil counts but not lymphocyte counts. The highest NLR quartile (&gt;3.11) was associated with an increased risk of exacerbation over 1 year (adjusted odds ratio, 1.51; 95% confidence interval, 1.18, 1.92) and increased risk of mortality (adjusted hazard ratio, 1.41; 95% confidence interval, 1.20, 1.66) compared with quartiles 1–3. Conclusions Elevated NLR in stable COPD is a widely available biomarker associated with increased risk for exacerbation and death. The impact of cigarette smoking on NLR varies with disease severity.
Applying High-reliability Principles to Infusion Pump Safety: A Case Study at a Multisite Health System
West, Ann , Schueler, Nicole, Moody, Rachel, Andersen, Merissa T., Dinsmore, Jill S., Miller, David B. , Wickens, Charles D., Byom, Pauline M., Lehnertz, Andrea Y., Ramar, Kannan , West, Ann M, West, Ann M., Andersen, Merissa T.

Mayo Clinic

Journal of Patient Safety | September 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pts.0000000000001395 | PMID 40919878 Get It

Objectives: A framework of high-reliability principles was used to identify, investigate, and mitigate infusion pump safety concerns at a large, multisite health care system. We developed a systematic approach to address challenges associated with overinfusions, underinfusions, and the inability to clear upstream occlusion alarms. We identified 112,875 upstream occlusion events for 389,604 infusion starts (failure rate, 29%) within 6 months. Methods: Five high-reliability principles were applied to infusion pump management. Preoccupation with failure emphasized reporting safety concerns and performing appropriate clinical and bench tests. Deference to expertise prompted the development of a multidisciplinary team with internal and external partners. Sensitivity to operations prompted assessment of human factors design, with simulations and analysis of medication-specific factors (e.g., viscosity; infusion rates). Reluctance to simplify prompted assessment of tubing characteristics (e.g., concentricity; wall thickness) with micro–computed tomography and process development for removing faulty equipment. Practice of resilience ensured ongoing engagement and commitment to a culture of safety and patient advocacy. Results: The multidisciplinary oversight team prompted a national recall, removal of malfunctioning pumps, and development of system-wide training and mitigation protocols. Despite ongoing pump challenges, our team optimized internal patient safety systems and processes. The cause of these malfunctions remains under investigation, but serious patient harm has been prevented. Conclusions: Key strategies for enhancing patient safety were continuous vigilance, interdisciplinary collaboration, and embracing complexity in a large health care organization. Future directions involve deeply integrating these high-reliability principles across all aspects of health care delivery to continue improving safety and quality outcomes.